Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 69Leukemia, Myeloid, Acute 32Carcinoma, Renal Cell 27Neoplasm Metastasis 17Breast Neoplasms 16Leukemia 15Neuroblastoma 14Kidney Neoplasms 14Lymphoma, Non-Hodgkin 12Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Myelodysplastic Syndromes 10Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Congenital Abnormalities 7Colorectal Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Skin Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Mesothelioma, Malignant 4Lung Neoplasms 4

Interventions

fludarabine 1Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Select Advanced Solid Tumors × Interleukin-2 × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡